Subprophylactic anti-Xa levels linked to higher venous thromboembolism risk in critically ill adults receiving low-molecular-weight heparin

A comprehensive systematic review and meta-analysis evaluated the relationship between subprophylactic anti-Xa levels and venous thromboembolism risk in critically ill adults receiving low-molecular-weight heparin. The study pooled data from multiple trials involving 7,124 patients within critical care settings to determine the prevalence of inadequate anticoagulation and its clinical consequences. The primary objective was to quantify the proportion of patients who achieved therapeutic anti-Xa targets and to assess the association between subtherapeutic levels and adverse thrombotic events. Secondary objectives included identifying patient characteristics that predicted the occurrence of subprophylactic anti-Xa concentrations.

The analysis demonstrated that only 47% of patients achieved the target anti-Xa levels required for effective thromboprophylaxis. This finding indicates that more than half of the critically ill population remains at risk for clot formation despite standard dosing regimens. The study calculated an unadjusted odds ratio of 2.87 for venous thromboembolism associated with subprophylactic anti-Xa levels. The 95% confidence interval for this association ranged from 1.42 to 5.81, confirming a statistically significant increase in risk. This magnitude of effect underscores the potential clinical impact of inadequate monitoring and dosing adjustments in high-risk populations.

Predictors of subprophylactic anti-Xa levels were identified through multivariate analysis. Male sex showed a moderate certainty association with lower anti-Xa concentrations, with an adjusted odds ratio of 2.65. The confidence interval for this association was 1.07 to 6.56, suggesting that male gender is an independent risk factor for inadequate anticoagulation. Additionally, increased body weight was significantly associated with subprophylactic levels. The mean difference in weight was 4.90 kg, with a confidence interval of 2.78 to 7.02. This suggests that higher body mass may dilute anticoagulant effects or alter drug distribution.

Elevated body mass index also correlated with subprophylactic anti-Xa levels. The mean difference was 1.36 per kg/m², with a confidence interval of 0.64 to 2.09. These findings imply that obesity or higher BMI requires careful consideration when calculating low-molecular-weight heparin doses. Clinicians must recognize that standard weight-based dosing may not account for pharmacokinetic variations in heavier patients. The moderate certainty of evidence for these predictors warrants further investigation but supports current clinical suspicion.

The study did not report specific adverse events, serious adverse events, discontinuations, or tolerability data. This limitation reflects the focus on efficacy and risk prediction rather than safety profiling. However, the association between subprophylactic levels and venous thromboembolism suggests that inadequate anticoagulation directly contributes to morbidity. The low certainty of evidence regarding the VTE risk association necessitates cautious interpretation. Factors such as study heterogeneity and potential publication bias may influence the overall conclusions. Despite these limitations, the clinical relevance remains high.

Monitoring anti-Xa levels is essential for optimizing thromboprophylaxis in critically ill adults. The data supports a shift from fixed dosing to therapeutic drug monitoring to ensure adequate coverage. Clinicians should consider patient-specific factors like sex and body mass when interpreting anti-Xa results. Future research should aim to distinguish association from causation and explore interventions to improve target achievement. Ultimately, these findings advocate for routine anti-Xa monitoring to reduce venous thromboembolism incidence in critical care.